Management of Cirrhosis Due to Genetic Factors

Diagnosis and Assessment

Antiviral treatment is strongly recommended for patients with compensated cirrhosis (Child-Pugh A) due to genetic factors, as HCV eradication decreases the risk of long-term complications such as progression to decompensated cirrhosis or development of hepatocellular carcinoma, according to the American Association for the Study of Liver Diseases 1

For HCV-related cirrhosis, the European Association for the Study of the Liver recommends treatment-naïve and treatment-experienced patients with compensated (Child-Pugh A) cirrhosis should receive either a fixed-dose combination of sofosbuvir and velpatasvir for 12 weeks, or a fixed-dose combination of glecaprevir and pibrentasvir for 8-12 weeks (depending on genotype and treatment history) 2, 3
For HBV-related cirrhosis, the American Association for the Study of Liver Diseases recommends long-term oral antiviral therapy using nucleoside/nucleotide analogues, with the choice of drug based on antiviral efficacy, side effects, and genetic barriers to drug-resistant viruses 4

The American Association for the Study of Liver Diseases recommends screening for gastroesophageal varices with endoscopy, and for primary prophylaxis of bleeding from gastric varices, non-selective beta blockers (NSBBs) are recommended as the primary approach, with cyanoacrylate injection ("glue") as the preferred endoscopic hemostasis option for acute gastric variceal hemorrhage 5
The European Association for the Study of the Liver recommends monitoring for spontaneous bacterial peritonitis (SBP) with diagnostic paracentesis when clinically indicated, and antibiotic prophylaxis for SBP is indicated in high-risk patients 5

The American Association for the Study of Liver Diseases recommends screening for hepatocellular carcinoma with ultrasound every 6 months, and continuous monitoring for cirrhosis-related complications is needed even after reaching sustained virologic response (SVR) in patients with viral hepatitis 6, 1, 7

The American Association for the Study of Liver Diseases recommends evaluating for liver transplantation in patients with decompensated cirrhosis (Child-Pugh C), and standard antiviral treatment regimens may be contraindicated due to the risk of severe complications 1

Despite achieving SVR in viral hepatitis, the risk of hepatocellular carcinoma or complications of chronic liver disease still exists in patients with cirrhosis or advanced hepatic fibrosis, according to the American Association for the Study of Liver Diseases 7
Cirrhotic patients often have hematological problems due to portal hypertension and splenomegaly, requiring careful monitoring during treatment, and growth factors such as recombinant erythropoietin or G-CSF can help overcome hematological complications during treatment 1